News

Liza M. Cohen, MD, explains when to use CT vs MRI in thyroid eye disease and why to review images yourself.

Anjum F. Koreishi, MD, explains why inflammation control and planning are key to cataract surgery for patients with uveitis.

FDA accepts vamikibart BLA for UME as data show sustained gains at 1 year; decision July 2027.

Liangbo Shen, MD, discussed unmet needs in geographic atrophy and how implants could ease treatment burden.

FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.

Vaidehi Dedania, MD, shared what the first whole eye transplant revealed about reperfusion, retinal cells, and sight.

Timothy Janetos, MD, outlined can’t-miss uveitis diagnoses, warning signs, and why every new patient needs dilation.

The evidence for nutrition in eye care is strong for some conditions and thin or absent for others.

A successful premium outcome depends not only on the lens, but also on how well the patient understands what to expect before surgery.

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.

Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.

John A. Hovanesian, MD, discusses the Armenian Eyecare Project’s annual trip, from preparation and surgery to teaching and student involvement.

At AAO 2026, Michael T. Yen, MD, reviewed REVEAL-1 efficacy and hearing safety data for subcutaneous elegrobart in active TED.

John J. Chen, MD, PhD, of Mayo Clinic discusses how NMOSD and MOGAD antibodies are changing optic neuritis care and the two trials now enrolling.

Twice-daily clobetasol 0.05% cleared cells in 26.5% vs 8.6% of patients and pain in 75.1% vs 32.4% after cataract surgery, with no added endothelial cell loss.

Initial phaco for angle-closure glaucoma climbed to 48.4% in adults 50 and older, while surveys and IRIS data show shifting trabeculectomy and JOAG surgical patterns.

Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.

A cataract expert discussed if postoperative topical antibiotics add protection after intracameral prophylaxis.

Donald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular edema.

Mark J. Gallardo, MD, discusses how the laser performed alongside cataract surgery in open-angle glaucoma, including medication burden and safety.

Oral PKC inhibitor darovasertib preserved the eye in 57% of patients facing enucleation and cut projected radiation doses in 70.3% in the phase 2 OptimUM-09 trial.

Drew Carey, MD, and Andrew G. Lee, MD, discuss triage, visual fields, double vision, and cataract topics from Neuro-Ophthalmology Subspecialty Day.

Noguchi FS formula error was 0.280 D in 486 eyes, LAL piggyback cut residual cylinder to 0.1 D, and Yamane and Gore-Tex fixation showed distinct complication profiles.

At AAO 2026 Retina Subspecialty Day, SriniVas Sadda, MD, outlined limits of current GA growth metrics and introduced border advancement pace and a location-weighted GA severity score.

In the phase 3 RESTORE-3 trial of 116 Chinese participants, the anti-IGF-1R antibody produced a 60.4% proptosis response rate vs 23.5% with placebo at week 24.

The concerns of October 10, 1857, sound remarkably familiar today.